ClinicalTrials.gg
RecruitingNCT07352852BRIDGE-INTRAUpdated Jan 20, 2026

Rapamycin-Eluting Vertebral Stents In The Real-World Treatment of Symptomatic Intracranial Atherosclerotic Stenosis

An observational study in Intracranial Arterial Stenosis and Brain Diseases, sponsored by The Affiliated Hospital of Qingdao University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by The Affiliated Hospital of Qingdao University · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Brain Diseases with a site in China — 18 open to participants now, 19 under way, 1 of them phase 3. Brain Diseases · China.

Planned enrollment
10th of 13
300 · median 600
Started
2025
with 7 others
Observational
13 of 41
7 open now
Primary completion
2027-12
later than 11 of 18 live
Registered
41st of 41
by date

Among the 41 studies in Brain Diseases with a site in China, this one is the 10th largest by planned enrollment of the 13 observational ones that give a count, is one of 8 that started in 2025, is one of 13 observational ones, reaches primary completion later than 11 of the 18 other live ones, and was the 41st registered.

Brain Diseases

502 studies on the registry are indexed under Brain Diseases; 141 are open to participants now.

Browse Brain Diseases studies →

Open to participants now

18 of the 41 studies in Brain Diseases with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 109 Brain Diseases studies recruiting now, 53 (49%) set no upper age limit and 22 (20%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Brain Diseases with a site in China, or all of them as a file.
02

Study summary

This clinical trial is a prospective, multicenter, single-arm study. About 300 subjects undergoing rapamycin-eluting stent implantation will be enrolled based on the inclusion and exclusion criteria. The primary endpoint is the rate of any stroke or death within 1 month. Secondary efficacy endpoints include immediate stent implantation success. Safety endpoints cover the incidence of stroke or neurological death, target-vessel-related stroke or death, all-cause mortality, and mRS scores at 12-month follow-ups. Subjects will be clinically followed up before surgery, device implantation, discharge, and at 1, 6, and 12 months post-surgery. An imaging subgroup of at least 80 subjects who agree to DSA follow-up at 12 months will assess in-stent restenosis (>50%).

03

Conditions studied

  • Intracranial Arterial Stenosis
  • Brain Diseases

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

subjects undergoing rapamycin-eluting stent implantation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 and ≤80 years;
  • Symptomatic intracranial atherosclerotic stenosis patients with ineffective medical treatment;
  • Digital subtraction angiography (DSA) shows target lesion stenosis ≥70%;
  • Suitable for implantation of rapamycin-targeted drug-eluting stents;
  • The patient and/or their authorized representative can understand the study purpose, agree to participate, and sign the form.

Exclusion criteria

Exclusion Criteria:

  • Modified Rankin Scale (mRS) score ≥3;
  • Ischemic stroke within the past 2 weeks;
  • Presence of more than 2 intracranial atherosclerotic stenosis lesions requiring interventional treatment;
  • Severe to heparin, aspirin, ticagrelor, clopidogrel, or other antiplatelet drugs, and inability to tolerate anticoagulant/antiplatelet therapy;
  • Severe dysfunction of major organs (e.g., severe hepatic insufficiency, renal insufficiency, heart failure);
  • Severe allergies to contrast agents, rapamycin and its derivatives, cobalt-based alloys, or polylactic acid;
  • Pregnant or lactating women;
  • Participation in other drug or device studies without reaching the endpoint;
  • less than 12 months;
  • Lesions or vascular access deemed unsuitable for rapamycin drug-eluting stent implantation by the operator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • exposed group

    subjects undergoing rapamycin-eluting stent implantation

06

What researchers measure

Primary outcomes

  1. Incidence of any stroke or death within 1 month after the procedure

    Time frame: 1 month

Secondary outcomes

  1. Incidence of in-stent restenosis (stenosis degree >50%) at 1year (imaging subgroup)

    Time frame: 1 year

  2. Immediate techenical success rate of stent implantation (imaging subgroup)

    Time frame: immediately after the intervention

  3. Incidence of stroke or neurogenic death within 1-year follow-up

    Time frame: 1 year

  4. Incidence of target vessel-related stroke or death within 1-year follow-up

    Time frame: 1 year

  5. All-cause mortality within 1-year follow-up

    Time frame: 1 year

  6. mRS score at 1-year follow-up

    mRS≥2

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2027, 31 months after the start.

Of 80 non-industry observational studies under Brain Diseases, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 193. This study's planned 31 months is below that.

Counting every sponsor, half of 89 studies reached it within 62 months; a quarter within 23 and three quarters within 193.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2025
First posted
Jan 20, 2026
StartActual
May 14, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07352852
Responsible party
zhangyong (Chief Physician, Department of Neurointerventional Medicine, The Affiliated Hospital of Qingdao University, The Affiliated Hospital of Qingdao University) — Principal investigator
First posted
Jan 20, 2026
Start date
May 14, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jan 20, 2026

Study contacts

Yong Zhang
Contact
bravezhang@126.com
(+86) 18661818866

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion